1 Report Business Overview 1.1 Study Scope 1.2 Market Analysis by Type 1.2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 1.2.2 Chemotherapy 1.2.3 Peptide-Receptor Radionuclide Therapy 1.2.4 Others 1.3 Market by Application 1.3.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Ambulatory Surgical Centers 1.3.5 Others 1.4 Study Objectives 1.5 Years Considered 2 Global Growth Trends 2.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Perspective (2017-2028) 2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Growth Trends by Region 2.2.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region: 2017 VS 2021 VS 2028 2.2.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Region (2017-2022) 2.2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Region (2023-2028) 2.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Dynamics 2.3.1 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Industry Trends 2.3.2 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers 2.3.3 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges 2.3.4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints 3 Competition Landscape by Key Players 3.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue 3.1.1 Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Revenue (2017-2022) 3.1.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Players (2017-2022) 3.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 3.3 Players Covered: Ranking by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue 3.4 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio 3.4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Concentration Ratio (CR5 and HHI) 3.4.2 Global Top 10 and Top 5 Companies by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2021 3.5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Key Players Head office and Area Served 3.6 Key Players Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Solution and Service 3.7 Date of Enter into Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market 3.8 Mergers & Acquisitions, Expansion Plans 4 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Type 4.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Type (2017-2022) 4.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2023-2028) 5 Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Breakdown Data by Application 5.1 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Historic Market Size by Application (2017-2022) 5.2 Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2023-2028) 6 North America 6.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2017-2028) 6.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type 6.2.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) 6.2.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2023-2028) 6.2.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2017-2028) 6.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application 6.3.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) 6.3.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2023-2028) 6.3.3 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2017-2028) 6.4 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country 6.4.1 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2017-2022) 6.4.2 North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2023-2028) 6.4.3 U.S. 6.4.4 Canada 7 Europe 7.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2017-2028) 7.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type 7.2.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) 7.2.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2023-2028) 7.2.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2017-2028) 7.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application 7.3.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) 7.3.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2023-2028) 7.3.3 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2017-2028) 7.4 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country 7.4.1 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2017-2022) 7.4.2 Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2023-2028) 7.4.3 Germany 7.4.4 France 7.4.5 U.K. 7.4.6 Italy 7.4.7 Russia 7.4.8 Nordic Countries 8 Asia-Pacific 8.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2017-2028) 8.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type 8.2.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) 8.2.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2023-2028) 8.2.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2017-2028) 8.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application 8.3.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) 8.3.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2023-2028) 8.3.3 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2017-2028) 8.4 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region 8.4.1 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2017-2022) 8.4.2 Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2023-2028) 8.4.3 China 8.4.4 Japan 8.4.5 South Korea 8.4.6 Southeast Asia 8.4.7 India 8.4.8 Australia 9 Latin America 9.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2017-2028) 9.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type 9.2.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) 9.2.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2023-2028) 9.2.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2017-2028) 9.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application 9.3.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) 9.3.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2023-2028) 9.3.3 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2017-2028) 9.4 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country 9.4.1 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2017-2022) 9.4.2 Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2023-2028) 9.4.3 Mexico 9.4.4 Brazil 10 Middle East & Africa 10.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (2017-2028) 10.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type 10.2.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) 10.2.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2023-2028) 10.2.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type (2017-2028) 10.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application 10.3.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) 10.3.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2023-2028) 10.3.3 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application (2017-2028) 10.4 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country 10.4.1 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2017-2022) 10.4.2 Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2023-2028) 10.4.3 Turkey 10.4.4 Saudi Arabia 10.4.5 UAE 11 Key Players Profiles 11.1 Novartis 11.1.1 Novartis Company Details 11.1.2 Novartis Business Overview 11.1.3 Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction 11.1.4 Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) 11.1.5 Novartis Recent Developments 11.2 Pfizer 11.2.1 Pfizer Company Details 11.2.2 Pfizer Business Overview 11.2.3 Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction 11.2.4 Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) 11.2.5 Pfizer Recent Developments 11.3 Fresenius Kabi 11.3.1 Fresenius Kabi Company Details 11.3.2 Fresenius Kabi Business Overview 11.3.3 Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction 11.3.4 Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) 11.3.5 Fresenius Kabi Recent Developments 11.4 Teva Pharmaceuticals 11.4.1 Teva Pharmaceuticals Company Details 11.4.2 Teva Pharmaceuticals Business Overview 11.4.3 Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction 11.4.4 Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) 11.4.5 Teva Pharmaceuticals Recent Developments 11.5 Sun Pharma 11.5.1 Sun Pharma Company Details 11.5.2 Sun Pharma Business Overview 11.5.3 Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction 11.5.4 Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) 11.5.5 Sun Pharma Recent Developments 11.6 Hutchison China MediTech Limited 11.6.1 Hutchison China MediTech Limited Company Details 11.6.2 Hutchison China MediTech Limited Business Overview 11.6.3 Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction 11.6.4 Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) 11.6.5 Hutchison China MediTech Limited Recent Developments 11.7 Exelixis, Inc. 11.7.1 Exelixis, Inc. Company Details 11.7.2 Exelixis, Inc. Business Overview 11.7.3 Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction 11.7.4 Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) 11.7.5 Exelixis, Inc. Recent Developments 11.8 Tarveda Therapeutics 11.8.1 Tarveda Therapeutics Company Details 11.8.2 Tarveda Therapeutics Business Overview 11.8.3 Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Introduction 11.8.4 Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) 11.8.5 Tarveda Therapeutics Recent Developments 12 Analyst's Viewpoints/Conclusions 13 Appendix 13.1 Research Methodology 13.1.1 Methodology/Research Approach 13.1.2 Data Source 13.2 Author Details 13.3 Disclaimer

List of Tables Table 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Type (US$ Million), 2017 VS 2021 VS 2028 Table 2. Key Players of Chemotherapy Table 3. Key Players of Peptide-Receptor Radionuclide Therapy Table 4. Key Players of Others Table 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028 Table 6. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028 Table 7. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2017-2022) & (US$ Million) Table 8. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2017-2022) Table 9. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million) Table 10. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region (2023-2028) Table 11. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Trends Table 12. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Drivers Table 13. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Challenges Table 14. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Restraints Table 15. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue by Players (2017-2022) & (US$ Million) Table 16. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Players (2017-2022) Table 17. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2021) Table 18. Ranking of Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Companies by Revenue (US$ Million) in 2021 Table 19. Global 5 Largest Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue (CR5 and HHI) & (2017-2022) Table 20. Key Players Headquarters and Area Served Table 21. Key Players Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Solution and Service Table 22. Date of Enter into Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Table 23. Mergers & Acquisitions, Expansion Plans Table 24. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) & (US$ Million) Table 25. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2017-2022) Table 26. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million) Table 27. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Market Share by Type (2023-2028) Table 28. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) & (US$ Million) Table 29. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Application (2017-2022) Table 30. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million) Table 31. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue Share by Application (2023-2028) Table 32. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) & (US$ Million) Table 33. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2023-2028) & (US$ Million) Table 34. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) & (US$ Million) Table 35. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2023-2028) & (US$ Million) Table 36. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 37. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 38. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) & (US$ Million) Table 39. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2023-2028) & (US$ Million) Table 40. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) & (US$ Million) Table 41. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2023-2028) & (US$ Million) Table 42. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 43. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 44. Asia Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) & (US$ Million) Table 45. Asia Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2023-2028) & (US$ Million) Table 46. Asia Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) & (US$ Million) Table 47. Asia Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2023-2028) & (US$ Million) Table 48. Asia Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2017-2022) & (US$ Million) Table 49. Asia Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Region (2023-2028) & (US$ Million) Table 50. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) & (US$ Million) Table 51. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2023-2028) & (US$ Million) Table 52. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) & (US$ Million) Table 53. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2023-2028) & (US$ Million) Table 54. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 55. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 56. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2017-2022) & (US$ Million) Table 57. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Type (2023-2028) & (US$ Million) Table 58. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2017-2022) & (US$ Million) Table 59. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Application (2023-2028) & (US$ Million) Table 60. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2017-2022) & (US$ Million) Table 61. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size by Country (2023-2028) & (US$ Million) Table 62. Novartis Company Details Table 63. Novartis Business Overview Table 64. Novartis Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Table 65. Novartis Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) & (US$ Million) Table 66. Novartis Recent Developments Table 67. Pfizer Company Details Table 68. Pfizer Business Overview Table 69. Pfizer Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Table 70. Pfizer Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) & (US$ Million) Table 71. Pfizer Recent Developments Table 72. Fresenius Kabi Company Details Table 73. Fresenius Kabi Business Overview Table 74. Fresenius Kabi Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Table 75. Fresenius Kabi Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) & (US$ Million) Table 76. Fresenius Kabi Recent Developments Table 77. Teva Pharmaceuticals Company Details Table 78. Teva Pharmaceuticals Business Overview Table 79. Teva Pharmaceuticals Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Table 80. Teva Pharmaceuticals Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) & (US$ Million) Table 81. Teva Pharmaceuticals Recent Developments Table 82. Sun Pharma Company Details Table 83. Sun Pharma Business Overview Table 84. Sun Pharma Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Table 85. Sun Pharma Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) & (US$ Million) Table 86. Sun Pharma Recent Developments Table 87. Hutchison China MediTech Limited Company Details Table 88. Hutchison China MediTech Limited Business Overview Table 89. Hutchison China MediTech Limited Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Table 90. Hutchison China MediTech Limited Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) & (US$ Million) Table 91. Hutchison China MediTech Limited Recent Developments Table 92. Exelixis, Inc. Company Details Table 93. Exelixis, Inc. Business Overview Table 94. Exelixis, Inc. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Table 95. Exelixis, Inc. Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) & (US$ Million) Table 96. Exelixis, Inc. Recent Developments Table 97. Tarveda Therapeutics Company Details Table 98. Tarveda Therapeutics Business Overview Table 99. Tarveda Therapeutics Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Product Table 100. Tarveda Therapeutics Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) & (US$ Million) Table 101. Tarveda Therapeutics Recent Developments Table 102. Research Programs/Design for This Report Table 103. Key Data Information from Secondary Sources Table 104. Key Data Information from Primary Sources List of Figures Figure 1. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Type: 2021 VS 2028 Figure 2. Chemotherapy Features Figure 3. Peptide-Receptor Radionuclide Therapy Features Figure 4. Others Features Figure 5. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Application: 2021 VS 2028 Figure 6. Hospitals Case Studies Figure 7. Clinics Case Studies Figure 8. Ambulatory Surgical Centers Case Studies Figure 9. Others Case Studies Figure 10. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Report Years Considered Figure 11. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028 Figure 12. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028 Figure 13. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Region: 2021 VS 2028 Figure 14. Global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Share by Players in 2021 Figure 15. Global Top Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics as of 2021) Figure 16. The Top 10 and 5 Players Market Share by Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Revenue in 2021 Figure 17. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY (2017-2028) & (US$ Million) Figure 18. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Market Share by Type (2017-2028) Figure 19. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Market Share by Application (2017-2028) Figure 20. North America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Share by Country (2017-2028) Figure 21. United States Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 22. Canada Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 23. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY (2017-2028) & (US$ Million) Figure 24. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Market Share by Type (2017-2028) Figure 25. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Market Share by Application (2017-2028) Figure 26. Europe Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Share by Country (2017-2028) Figure 27. Germany Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 28. France Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 29. U.K. Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 30. Italy Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 31. Russia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 32. Nordic Countries Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 33. Asia-Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY (2017-2028) & (US$ Million) Figure 34. Asia Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Market Share by Type (2017-2028) Figure 35. Asia Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Market Share by Application (2017-2028) Figure 36. Asia Pacific Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Share by Region (2017-2028) Figure 37. China Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 38. Japan Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 39. South Korea Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 40. Southeast Asia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 41. India Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 42. Australia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) List of Figures Figure 43. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY (2017-2028) & (US$ Million) Figure 44. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Market Share by Type (2017-2028) Figure 45. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Market Share by Application (2017-2028) Figure 46. Latin America Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Share by Country (2017-2028) Figure 47. Mexico Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 48. Brazil Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 49. Middle East & Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY (2017-2028) & (US$ Million) Figure 50. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Market Share by Type (2017-2028) Figure 51. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Market Share by Application (2017-2028) Figure 52. Middle East and Africa Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size Share by Country (2017-2028) Figure 53. Turkey Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 54. Saudi Arabia Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 55. UAE Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million) Figure 56. Novartis Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) Figure 57. Pfizer Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) Figure 58. Fresenius Kabi Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) Figure 59. Teva Pharmaceuticals Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) Figure 60. Sun Pharma Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) Figure 61. Hutchison China MediTech Limited Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) Figure 62. Exelixis, Inc. Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) Figure 63. Tarveda Therapeutics Revenue Growth Rate in Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Business (2017-2022) Figure 64. Bottom-up and Top-down Approaches for This Report Figure 65. Data Triangulation Figure 66. Key Executives Interviewed

Novartis Pfizer Fresenius Kabi Teva Pharmaceuticals Sun Pharma Hutchison China MediTech Limited Exelixis, Inc. Tarveda Therapeutics